Cargando…
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia
BACKGROUND: The recently developed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mRNA vaccine has a short history of use and further information is needed regarding its efficacy, especially in immunocompromised conditions, such as plasma cell dyscrasia (PCD). METHODS: We retrospective...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315730/ https://www.ncbi.nlm.nih.gov/pubmed/37102222 http://dx.doi.org/10.1002/cam4.5996 |
_version_ | 1785067560036728832 |
---|---|
author | Suzuki, Tomotaka Kusumoto, Shigeru Kamezaki, Yoshiko Hashimoto, Hiroya Nishitarumizu, Nozomi Nakanishi, Yoko Kato, Yukiyasu Kawai, Akimi Matsunaga, Naohiro Ebina, Toru Nakamura, Tomoyuki Marumo, Yoshiaki Oiwa, Kana Kinoshita, Shiori Narita, Tomoko Ito, Asahi Inagaki, Atsushi Ri, Masaki Komatsu, Hirokazu Aritsu, Takashi Iida, Shinsuke |
author_facet | Suzuki, Tomotaka Kusumoto, Shigeru Kamezaki, Yoshiko Hashimoto, Hiroya Nishitarumizu, Nozomi Nakanishi, Yoko Kato, Yukiyasu Kawai, Akimi Matsunaga, Naohiro Ebina, Toru Nakamura, Tomoyuki Marumo, Yoshiaki Oiwa, Kana Kinoshita, Shiori Narita, Tomoko Ito, Asahi Inagaki, Atsushi Ri, Masaki Komatsu, Hirokazu Aritsu, Takashi Iida, Shinsuke |
author_sort | Suzuki, Tomotaka |
collection | PubMed |
description | BACKGROUND: The recently developed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mRNA vaccine has a short history of use and further information is needed regarding its efficacy, especially in immunocompromised conditions, such as plasma cell dyscrasia (PCD). METHODS: We retrospectively measured serum SARS‐CoV‐2 antibodies against the spike protein (S‐IgG) after the second and third mRNA vaccine doses (doses 2 and 3, respectively) in 109 patients with PCD. We evaluated the proportion of patients with an adequate humoral response (defined as S‐IgG titers ≥300 antibody units/mL). RESULTS: Although active anti‐myeloma treatments prior to vaccination had a significantly negative impact on adequate humoral response, specific drug subclasses including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies were not negatively associated, except for B‐cell maturation antigen‐targeted therapy. Dose 3 (booster vaccination) led to significantly higher S‐IgG titers and more patients acquired an adequate humoral response. Furthermore, evaluation of vaccine‐induced cellular immune response in patients using T‐spot Discovery SARS‐CoV‐2 kit, revealed an enhanced cellular immune response after Dose 3. CONCLUSIONS: This study highlighted the significance of booster SARS‐CoV‐2 mRNA vaccination in patients with PCD with respect to humoral and cellular immunity. Moreover, this study highlighted the potential impact of certain drug subclasses on vaccine‐induced humoral immune response. |
format | Online Article Text |
id | pubmed-10315730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103157302023-07-04 Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia Suzuki, Tomotaka Kusumoto, Shigeru Kamezaki, Yoshiko Hashimoto, Hiroya Nishitarumizu, Nozomi Nakanishi, Yoko Kato, Yukiyasu Kawai, Akimi Matsunaga, Naohiro Ebina, Toru Nakamura, Tomoyuki Marumo, Yoshiaki Oiwa, Kana Kinoshita, Shiori Narita, Tomoko Ito, Asahi Inagaki, Atsushi Ri, Masaki Komatsu, Hirokazu Aritsu, Takashi Iida, Shinsuke Cancer Med RESEARCH ARTICLES BACKGROUND: The recently developed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mRNA vaccine has a short history of use and further information is needed regarding its efficacy, especially in immunocompromised conditions, such as plasma cell dyscrasia (PCD). METHODS: We retrospectively measured serum SARS‐CoV‐2 antibodies against the spike protein (S‐IgG) after the second and third mRNA vaccine doses (doses 2 and 3, respectively) in 109 patients with PCD. We evaluated the proportion of patients with an adequate humoral response (defined as S‐IgG titers ≥300 antibody units/mL). RESULTS: Although active anti‐myeloma treatments prior to vaccination had a significantly negative impact on adequate humoral response, specific drug subclasses including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies were not negatively associated, except for B‐cell maturation antigen‐targeted therapy. Dose 3 (booster vaccination) led to significantly higher S‐IgG titers and more patients acquired an adequate humoral response. Furthermore, evaluation of vaccine‐induced cellular immune response in patients using T‐spot Discovery SARS‐CoV‐2 kit, revealed an enhanced cellular immune response after Dose 3. CONCLUSIONS: This study highlighted the significance of booster SARS‐CoV‐2 mRNA vaccination in patients with PCD with respect to humoral and cellular immunity. Moreover, this study highlighted the potential impact of certain drug subclasses on vaccine‐induced humoral immune response. John Wiley and Sons Inc. 2023-04-26 /pmc/articles/PMC10315730/ /pubmed/37102222 http://dx.doi.org/10.1002/cam4.5996 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Suzuki, Tomotaka Kusumoto, Shigeru Kamezaki, Yoshiko Hashimoto, Hiroya Nishitarumizu, Nozomi Nakanishi, Yoko Kato, Yukiyasu Kawai, Akimi Matsunaga, Naohiro Ebina, Toru Nakamura, Tomoyuki Marumo, Yoshiaki Oiwa, Kana Kinoshita, Shiori Narita, Tomoko Ito, Asahi Inagaki, Atsushi Ri, Masaki Komatsu, Hirokazu Aritsu, Takashi Iida, Shinsuke Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia |
title | Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia |
title_full | Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia |
title_fullStr | Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia |
title_full_unstemmed | Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia |
title_short | Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia |
title_sort | humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mrna vaccine in patients with plasma cell dyscrasia |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315730/ https://www.ncbi.nlm.nih.gov/pubmed/37102222 http://dx.doi.org/10.1002/cam4.5996 |
work_keys_str_mv | AT suzukitomotaka humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT kusumotoshigeru humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT kamezakiyoshiko humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT hashimotohiroya humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT nishitarumizunozomi humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT nakanishiyoko humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT katoyukiyasu humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT kawaiakimi humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT matsunaganaohiro humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT ebinatoru humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT nakamuratomoyuki humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT marumoyoshiaki humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT oiwakana humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT kinoshitashiori humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT naritatomoko humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT itoasahi humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT inagakiatsushi humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT rimasaki humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT komatsuhirokazu humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT aritsutakashi humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia AT iidashinsuke humoralandcellularimmuneresponsetosecondandthirdsevereacuterespiratorysyndromecoronavirus2mrnavaccineinpatientswithplasmacelldyscrasia |